Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs

Prelude Therapeutics (PRLD) the first preclinical data on its JAK2V617F mutant selective JH2 inhibitors and additional preclinical data from its mCALR-targeted degrader antibody conjugate discovery program. Both oral presentations took place at the American Society of Hematology, ASH, 67th Annual Meeting in Orlando, FL. These presentations can be found at Publications – Prelude Therapeutics. Key highlights: First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms; PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026; First disclosure of a mutant calreticulin targeted degrader antibody conjugate with a novel CDK9 degrader payload; JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients